Product image of Metlinka 50 Mg/850 Mg (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metlinka 50 Mg/850 Mg

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metlinka 50 Mg/850 Mg (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka 50 Mg/850 Mg, is a Biguanide/DPP‑4 inhibitor presented as an 850 mg/50 mg oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, providing combined glucose‑lowering effects through complementary mechanisms.

GNH India supplies Metlinka 50 Mg/850 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Manufacturer / TM Owner

Tchaikapharma High Quality Medicines, Inc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Metlinka 50 Mg/850 Mg is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.
  • Type 2 diabetes mellitus: improves overall glycemic control when added to metformin monotherapy.
  • Adults with inadequate HbA1c reduction on metformin alone: provides additional DPP‑4 inhibition to further lower blood glucose.
  • Patients requiring a weight‑neutral regimen: offers glucose lowering without promoting weight gain.

How It Works

  • Metlinka combines metformin, which suppresses hepatic gluconeogenesis and enhances peripheral insulin sensitivity, with sitagliptin, a selective dipeptidyl peptidase‑4 inhibitor that prevents degradation of incretin hormones (GLP‑1 and GIP). The resulting increase in endogenous incretin activity stimulates glucose‑dependent insulin secretion while reducing glucagon release, complementing metformin’s actions to achieve better overall blood glucose reduction.

Side Effects

Metlinka may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Upper respiratory symptoms: nasopharyngitis or sore throat.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic complication.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

  • When prescribing Metlinka, clinicians should consider several precautionary measures to ensure patient safety.
  • Renal function: assess eGFR before initiating therapy and monitor periodically.
  • Hepatic impairment: use with caution and evaluate liver enzymes regularly.
  • Lactic acidosis risk: avoid in patients with conditions that predispose to hypoxia or severe infection.
  • Pregnancy and lactation: safety not established; discuss potential risks with the healthcare provider.
  • Drug interactions: review concomitant medications for possible pharmacokinetic or pharmacodynamic effects.
  • Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Avoid Interactions

Metlinka can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase sitagliptin plasma concentrations.
  • Co‑administration with metformin‑containing iodinated contrast agents can raise the risk of lactic acidosis.
  • Combination with sulfonylureas or insulin may cause severe hypoglycemia.
  • High‑dose alcohol intake may exacerbate metformin‑related toxicity.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin, requiring dose adjustment.
  • Beta‑blockers: can mask typical hypoglycemia symptoms, necessitating closer glucose monitoring.
  • ACE inhibitors or ARBs: concurrent use may warrant periodic renal function assessment.

Frequently Asked Questions

Metlinka 50 Mg/850 Mg is a fixed‑dose combination of metformin hydrochloride and sitagliptin indicated for the treatment of type 2 diabetes mellitus in adults, typically as an adjunct to diet and exercise to improve glycemic control.

Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity, while sitagliptin inhibits the enzyme DPP‑4, prolonging the activity of incretin hormones that stimulate insulin release and suppress glucagon, together providing complementary glucose‑lowering effects.

The prescribed dose is determined by the treating physician based on individual clinical factors such as renal function, prior therapy, and glycemic targets; dosing adjustments are made according to professional guidelines.

Safety data in pregnancy and lactation are limited; the medication should only be used if the potential benefit justifies the potential risk, and decisions should be made in consultation with a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity; GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with metformin alone, the addition of sitagliptin offers greater HbA1c reduction without increasing risk of weight gain; versus sulfonylureas, it provides a lower hypoglycemia risk, and unlike GLP‑1 receptor agonists it is an oral tablet rather than an injectable.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container, protected from moisture and direct sunlight to maintain product stability.

Metlinka is taken orally, usually once daily with or without food, as directed by the prescribing clinician; tablets should be swallowed whole with water and not split or crushed unless advised.

The most critical concerns include the rare occurrence of lactic acidosis, severe hypoglycemia when combined with other glucose‑lowering agents, acute pancreatitis, and serious allergic reactions such as anaphylaxis; patients should seek immediate medical attention if these symptoms arise.

Individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any component of the formulation, and those with a history of lactic acidosis should avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT